L I Igel1, K H Saunders2, J J Fins3. 1. Division of Endocrinology, Diabetes and Metabolism, Comprehensive Weight Control Center, Weill Cornell Medical College, 1165 York Avenue, New York, NY, 10065, USA. lei9004@med.cornell.edu. 2. Division of Endocrinology, Diabetes and Metabolism, Comprehensive Weight Control Center, Weill Cornell Medical College, 1165 York Avenue, New York, NY, 10065, USA. 3. The E. William Davis, Jr., M.D. Professor of Medical Ethics, Professor of Medicine Chief, Division of Medical Ethics, Weill Cornell Medical College, New York, NY, USA.
Abstract
PURPOSE OF REVIEW: In this review, we examine one of the ironies of American health care-that we pay more for disease management than disease prevention. Instead of preventing type 2 diabetes (T2DM) by treating its precursor, obesity, we fail to provide sufficient insurance coverage for weight management only to fund the more costly burden of overt T2DM. RECENT FINDINGS: There is a vital need for expanded insurance coverage to help foster a weight-centric approach to T2DM management. This includes broader coverage of anti-diabetic medications with evidence of cardiovascular risk reduction and mortality benefit, anti-obesity pharmacotherapy, bariatric surgery, weight loss devices, endoscopic bariatric therapies, and lifestyle interventions for the treatment of obesity. The fundamental question to ask is why weight? Why wait to go after obesity until its end-stage sequelae cause intractable conditions? Instead of managing the complications of T2DM, consider preventing them by tackling obesity.
PURPOSE OF REVIEW: In this review, we examine one of the ironies of American health care-that we pay more for disease management than disease prevention. Instead of preventing type 2 diabetes (T2DM) by treating its precursor, obesity, we fail to provide sufficient insurance coverage for weight management only to fund the more costly burden of overt T2DM. RECENT FINDINGS: There is a vital need for expanded insurance coverage to help foster a weight-centric approach to T2DM management. This includes broader coverage of anti-diabetic medications with evidence of cardiovascular risk reduction and mortality benefit, anti-obesity pharmacotherapy, bariatric surgery, weight loss devices, endoscopic bariatric therapies, and lifestyle interventions for the treatment of obesity. The fundamental question to ask is why weight? Why wait to go after obesity until its end-stage sequelae cause intractable conditions? Instead of managing the complications of T2DM, consider preventing them by tackling obesity.
Entities:
Keywords:
Access to care; Diabetes prevention; Evidence-based medicine; Insurance coverage; Obesity treatment; Type 2 diabetes mellitus
Authors: Floris A van de Laar; Peter L Lucassen; Reinier P Akkermans; Eloy H van de Lisdonk; Guy E Rutten; Chris van Weel Journal: Diabetes Care Date: 2005-01 Impact factor: 19.112
Authors: Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich Journal: Lancet Date: 2010-07-29 Impact factor: 79.321
Authors: Johannes F E Mann; David D Ørsted; Kirstine Brown-Frandsen; Steven P Marso; Neil R Poulter; Søren Rasmussen; Karen Tornøe; Bernard Zinman; John B Buse Journal: N Engl J Med Date: 2017-08-31 Impact factor: 91.245
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Javad Sharifi-Rad; Célia F Rodrigues; Farukh Sharopov; Anca Oana Docea; Aslı Can Karaca; Mehdi Sharifi-Rad; Derya Kahveci Karıncaoglu; Gözde Gülseren; Ezgi Şenol; Evren Demircan; Yasaman Taheri; Hafiz Ansar Rasul Suleria; Beraat Özçelik; Kadriye Nur Kasapoğlu; Mine Gültekin-Özgüven; Ceren Daşkaya-Dikmen; William C Cho; Natália Martins; Daniela Calina Journal: Int J Environ Res Public Health Date: 2020-03-30 Impact factor: 3.390